These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. NHERF1 Enhances Cisplatin Sensitivity in Human Cervical Cancer Cells. Tao T; Yang X; Qin Q; Shi W; Wang Q; Yang Y; He J Int J Mol Sci; 2017 Jan; 18(1):. PubMed ID: 28085111 [TBL] [Abstract][Full Text] [Related]
10. The role of Dickkopf-3 overexpression in esophageal adenocarcinoma. Wang Z; Lin L; Thomas DG; Nadal E; Chang AC; Beer DG; Lin J J Thorac Cardiovasc Surg; 2015 Aug; 150(2):377-385.e2. PubMed ID: 26093488 [TBL] [Abstract][Full Text] [Related]
11. Identification and characterization of stemlike cells in human esophageal adenocarcinoma and normal epithelial cell lines. Zhao R; Quaroni L; Casson AG J Thorac Cardiovasc Surg; 2012 Nov; 144(5):1192-9. PubMed ID: 22980068 [TBL] [Abstract][Full Text] [Related]
12. Subtypes of Barrett's oesophagus and oesophageal adenocarcinoma based on genome-wide methylation analysis. Yu M; Maden SK; Stachler M; Kaz AM; Ayers J; Guo Y; Carter KT; Willbanks A; Heinzerling TJ; O'Leary RM; Xu X; Bass A; Chandar AK; Chak A; Elliott R; Willis JE; Markowitz SD; Grady WM Gut; 2019 Mar; 68(3):389-399. PubMed ID: 29884612 [TBL] [Abstract][Full Text] [Related]
13. Downregulation of IGFBP2 is associated with resistance to IGF1R therapy in rhabdomyosarcoma. Kang Z; Yu Y; Zhu YJ; Davis S; Walker R; Meltzer PS; Helman LJ; Cao L Oncogene; 2014 Dec; 33(50):5697-705. PubMed ID: 24292683 [TBL] [Abstract][Full Text] [Related]
14. HtrA1 downregulation induces cisplatin resistance in lung adenocarcinoma by promoting cancer stem cell-like properties. Xu Y; Jiang Z; Zhang Z; Sun N; Zhang M; Xie J; Li T; Hou Y; Wu D J Cell Biochem; 2014 Jun; 115(6):1112-21. PubMed ID: 24356998 [TBL] [Abstract][Full Text] [Related]
15. IGFBP2/FAK pathway is causally associated with dasatinib resistance in non-small cell lung cancer cells. Lu H; Wang L; Gao W; Meng J; Dai B; Wu S; Minna J; Roth JA; Hofstetter WL; Swisher SG; Fang B Mol Cancer Ther; 2013 Dec; 12(12):2864-73. PubMed ID: 24130049 [TBL] [Abstract][Full Text] [Related]
16. Drug-induced expression of EpCAM contributes to therapy resistance in esophageal adenocarcinoma. Sun X; Martin RCG; Zheng Q; Farmer R; Pandit H; Li X; Jacob K; Suo J; Li Y Cell Oncol (Dordr); 2018 Dec; 41(6):651-662. PubMed ID: 30116994 [TBL] [Abstract][Full Text] [Related]
17. Upregulation of MIIP regulates human breast cancer proliferation, invasion and migration by mediated by IGFBP2. Du Y; Wang P Pathol Res Pract; 2019 Jul; 215(7):152440. PubMed ID: 31078343 [TBL] [Abstract][Full Text] [Related]
18. Proton pump inhibitors (PPIs) impact on tumour cell survival, metastatic potential and chemotherapy resistance, and affect expression of resistance-relevant miRNAs in esophageal cancer. Lindner K; Borchardt C; Schöpp M; Bürgers A; Stock C; Hussey DJ; Haier J; Hummel R J Exp Clin Cancer Res; 2014 Sep; 33(1):73. PubMed ID: 25175076 [TBL] [Abstract][Full Text] [Related]
19. TGM2: a cell surface marker in esophageal adenocarcinomas. Leicht DT; Kausar T; Wang Z; Ferrer-Torres D; Wang TD; Thomas DG; Lin J; Chang AC; Lin L; Beer DG J Thorac Oncol; 2014 Jun; 9(6):872-81. PubMed ID: 24828664 [TBL] [Abstract][Full Text] [Related]
20. The PI3K/AKT pathway promotes gefitinib resistance in mutant KRAS lung adenocarcinoma by a deacetylase-dependent mechanism. Jeannot V; Busser B; Brambilla E; Wislez M; Robin B; Cadranel J; Coll JL; Hurbin A Int J Cancer; 2014 Jun; 134(11):2560-71. PubMed ID: 24374738 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]